BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 46 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q4 2021. The put-call ratio across all filers is 1.02 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $600 | -70.9% | 3,000 | +200.0% | 0.00% | -50.0% |
| Q2 2023 | $2,060 | -97.1% | 1,000 | -93.8% | 0.00% | -98.0% |
| Q3 2022 | $71,000 | +2266.7% | 16,000 | +1500.0% | 0.10% | +2425.0% |
| Q2 2022 | $3,000 | -50.0% | 1,000 | -33.3% | 0.00% | -20.0% |
| Q4 2021 | $6,000 | +50.0% | 1,500 | +50.0% | 0.01% | +66.7% |
| Q2 2021 | $4,000 | 0.0% | 1,000 | 0.0% | 0.00% | -25.0% |
| Q1 2021 | $4,000 | -20.0% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $5,000 | -44.4% | 1,000 | +100.0% | 0.00% | -50.0% |
| Q3 2020 | $9,000 | +50.0% | 500 | 0.0% | 0.01% | +33.3% |
| Q2 2020 | $6,000 | – | 500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 242,850 | $923,000 | 0.13% |
| ABNER HERRMAN & BROCK LLC | 241,500 | $918,000 | 0.13% |
| Weaver Consulting Group | 48,881 | $186,000 | 0.10% |
| Tibra Equities Europe Ltd | 87,000 | $331,000 | 0.10% |
| Ikarian Capital, LLC | 293,200 | $1,115,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 60,238 | $229,000 | 0.03% |
| Ergoteles LLC | 124,329 | $472,000 | 0.01% |
| CFO4Life Group, LLC | 12,003 | $46,000 | 0.01% |
| HighPoint Advisor Group LLC | 17,033 | $65,000 | 0.01% |
| BOOTHBAY FUND MANAGEMENT, LLC | 32,836 | $125,000 | 0.00% |